Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03558152 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
NCT03558152 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 195 participants.
The verdict
NCT03558152, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetics of UTTR1147A compared with vedolizumab and with placebo in the treatment of participants with moderate to severe UC. This study will consist of two parts, Part A and Part B. Part A will test the induction of clinical remission and Part B will test the durability of clinical remission.
Interventions
- DRUG Vedolizumab
- DRUG UTTR1147A
- DRUG UTTR1147A Placebo
- DRUG Vedolizumab Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2018-10-26 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03558152
The ClinicalTrials.gov registry entry for NCT03558152 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vedolizumab is the first listed.
NCT03558152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03558152 about?
NCT03558152 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)". This study is designed to evaluate the efficacy, safety, and pharmacokinetics of UTTR1147A compared with vedolizumab and with placebo in the treatment of participants with moderate to severe UC. This study will consist of two parts, Part A and Part B. Part A will test the induction of clinical remis...
What is the current status of trial NCT03558152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2018-10-26. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT03558152?
The interventions under investigation include: Vedolizumab (DRUG), UTTR1147A (DRUG), UTTR1147A Placebo (DRUG), Vedolizumab Placebo (DRUG).
Who is sponsoring clinical trial NCT03558152?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.